At press time, the Office of Inspector General issued its final compliance program guidance for pharmaceutical manufacturers, available at www.oig.hhs.gov.
The guidance has major implications for CME providers. It underscores that commercial supporters must not have influence over content orof CME. It also says “codes of conduct promulgated by the CME industry may provide a useful starting point for manufacturers when reviewing their CME arrangements.”
We will offer analysis and comments from the CME and pharmaceutical community in the July/August issue of MM.